DIAGNOSIS AND TREATMENT OF MYELOID DISORDERS AND ACUTE LEUKEMIAS USING NOVEL TUMOR SPECIFIC ANTIGENS

ABSTRACT

The present disclosure relates to a method of diagnosing or treating myeloid disorders and acute leukemias by using a tumor specific antigen selected from CD63, CD151, CD72, CD84, CD69, and CD109. Further provided are an antigen binding protein (ABP), an ABP-drug conjugate, and a CAR targeting the tumor specific antigen, and methods for their use.

No suitable figure